A combination vial pairing two complementary growth hormone secretagogues. CJC-1295 prompts the pituitary to increase growth hormone output in a natural pulse rhythm. Ipamorelin triggers that pulse through a separate receptor pathway — selectively, without raising cortisol or prolactin. Together they produce a stronger, more sustained GH release than either compound alone.
CJC-1295 (No DAC) is a GHRH analogue — it binds pituitary GHRH receptors and amplifies the natural GH pulse. Ipamorelin is a selective GHRP (growth hormone-releasing peptide) — it mimics ghrelin and activates the ghrelin receptor (GHSR), triggering GH release through a completely separate pathway. The dual-pathway mechanism creates a synergistic GH release: the two signals arrive simultaneously and produce a GH pulse larger than either could achieve alone, while ipamorelin's selectivity means there is no unwanted elevation of cortisol, prolactin, or ACTH.
Growth hormone and subsequently IGF-1 rise in a pulsatile, physiological pattern. Over weeks and months, this translates to improved lean mass accretion, fat mobilisation (particularly around the midsection), faster recovery from training and injury, deeper slow-wave sleep, and improvements in skin tone and collagen density.
Tesamorelin adds a GHRH signal — consult guidance before stacking, as GH elevation compounds
Pairs recovery and tissue repair with GH-driven lean mass and healing benefits
TB-500 accelerates systemic tissue healing — strong combination for athletic recovery cycles
Not medical advice. Not a substitute for medical care. Consult your licensed practitioner before beginning any protocol. Peptides are sold for research purposes only and are suitable for adults aged 18 years and over.